The extent and determinants of changes in CYP2D6 and CYP1A2 activities with therapeutic doses of sertraline
- PMID:9472843
- DOI: 10.1097/00004714-199802000-00009
The extent and determinants of changes in CYP2D6 and CYP1A2 activities with therapeutic doses of sertraline
Abstract
The extent of changes in CYP2D6 and CYP1A2 activities with higher therapeutic dosages (>50 mg/day) of sertraline is not well established in vivo. This study assessed the extent and determinants of changes in CYP2D6 and CYP1A2 isozyme activities after treatment with clinically relevant doses of sertraline. Patients and healthy volunteers aged 19 to 85 years (N = 21) were treated with sertraline for 5 to 55 days. The dosage of sertraline ranged from 25 to 150 mg/day (93.5+/-26.4 mg/day; mean +/- SD). All subjects had an extensive metabolizer phenotype for CYP2D6 and received a single oral dose of dextromethorphan (30 mg) and caffeine (100 mg) before and after sertraline treatment. The log O-demethylation ratio (ODMR) of dextromethorphan and the caffeine metabolic ratio (CMR) in overnight urine were used as in vivo indices of the CYP2D6 and CYP1A2 isozyme activities, respectively. Concurrent medications and lifestyle habits (e.g., smoking and diet) were monitored during the study. Baseline log ODMR (-2.33+/-0.45) but not CMR (5.1+/-1.9) (mean +/- SD) significantly changed after sertraline treatment (-2.19+/-0.62; 4.5+/-1.6, respectively) (p: ODMR = 0.04, CMR = 0.10). There was no significant effect of age, dose, duration of treatment, gender, sertraline and/or desmethylsertraline plasma concentration, subject type (patient or volunteer), and weight on the extent of changes in log ODMR or CMR (p > 0.05). In conclusion, sertraline treatment at a mean daily dosage of 94.0 mg did not significantly change CYP1A2 activity and resulted in a modest inhibition of CYP2D6 activity.
Similar articles
- Determinants of interindividual variability and extent of CYP2D6 and CYP1A2 inhibition by paroxetine and fluvoxamine in vivo.Ozdemir V, Naranjo CA, Shulman RW, Herrmann N, Sellers EM, Reed K, Kalow W.Ozdemir V, et al.J Clin Psychopharmacol. 1998 Jun;18(3):198-207. doi: 10.1097/00004714-199806000-00004.J Clin Psychopharmacol. 1998.PMID:9617978
- Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2.Ball SE, Ahern D, Scatina J, Kao J.Ball SE, et al.Br J Clin Pharmacol. 1997 Jun;43(6):619-26. doi: 10.1046/j.1365-2125.1997.00591.x.Br J Clin Pharmacol. 1997.PMID:9205822Free PMC article.
- CYP2D6 inhibition in patients treated with sertraline.Sproule BA, Otton SV, Cheung SW, Zhong XH, Romach MK, Sellers EM.Sproule BA, et al.J Clin Psychopharmacol. 1997 Apr;17(2):102-6. doi: 10.1097/00004714-199704000-00007.J Clin Psychopharmacol. 1997.PMID:10950472
- Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6.Ereshefsky L, Riesenman C, Lam YW.Ereshefsky L, et al.Clin Pharmacokinet. 1995;29 Suppl 1:10-8; discussion 18-9. doi: 10.2165/00003088-199500291-00004.Clin Pharmacokinet. 1995.PMID:8846618Review.
- Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism.Preskorn SH.Preskorn SH.Clin Pharmacokinet. 1997;32 Suppl 1:1-21. doi: 10.2165/00003088-199700321-00003.Clin Pharmacokinet. 1997.PMID:9068931Review.
Cited by
- Selecting a Selective Serotonin Reuptake Inhibitor: Clinically Important Distinguishing Features.Marken PA, Munro JS.Marken PA, et al.Prim Care Companion J Clin Psychiatry. 2000 Dec;2(6):205-210. doi: 10.4088/pcc.v02n0602.Prim Care Companion J Clin Psychiatry. 2000.PMID:15014630Free PMC article.
- PharmGKB summary: sertraline pathway, pharmacokinetics.Huddart R, Hicks JK, Ramsey LB, Strawn JR, Smith DM, Bobonis Babilonia M, Altman RB, Klein TE.Huddart R, et al.Pharmacogenet Genomics. 2020 Feb;30(2):26-33. doi: 10.1097/FPC.0000000000000392.Pharmacogenet Genomics. 2020.PMID:31851125Free PMC article.No abstract available.
- The selective serotonin reuptake inhibitor sertraline: its profile and use in psychiatric disorders.MacQueen G, Born L, Steiner M.MacQueen G, et al.CNS Drug Rev. 2001 Spring;7(1):1-24. doi: 10.1111/j.1527-3458.2001.tb00188.x.CNS Drug Rev. 2001.PMID:11420570Free PMC article.Review.
- Treatment of anxiety and depression in transplant patients: pharmacokinetic considerations.Crone CC, Gabriel GM.Crone CC, et al.Clin Pharmacokinet. 2004;43(6):361-94. doi: 10.2165/00003088-200443060-00002.Clin Pharmacokinet. 2004.PMID:15086275Review.
- The Impact of Sertraline Co-Administration on the Pharmacokinetics of Olanzapine: A Population Pharmacokinetic Analysis of the STOP-PD.Davies SJ, Mulsant BH, Flint AJ, Meyers BS, Rothschild AJ, Whyte EM, Kirshner MM, Sorisio D, Pollock BG, Bies RR.Davies SJ, et al.Clin Pharmacokinet. 2015 Nov;54(11):1161-8. doi: 10.1007/s40262-015-0275-1.Clin Pharmacokinet. 2015.PMID:25971243Clinical Trial.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources